Please login to the form below
Lenti-D
This page shows the latest Lenti-D news and features for those working in and with pharma, biotech and healthcare.
bluebird bio maintains its focus on gene therapy opportunities during structural changes
Indeed, if approved, betibeglogene autotemcel (beti-cel) for beta-thalassemia and elivaldogene autotemcel (eli-cel, Lenti-D) for cerebral adrenoleukodystrophy will be the first ex-vivo LVV gene therapies available in
Latest news
-
Gene therapy company bluebird bio quits Europe
Only three weeks after gaining approval in Europe for its gene therapy treatment Lenti-D (elivaldogene autotemcel or eli-cel), bluebird bio has announced it will “scale back operations in Europe ... While the company has not announced how much it asked
-
bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP
The CHMP has recommended marketing authorisation for Skysona (elivaldogene autotemcel, Lenti-D) for the early treatment of CALD in patients under 18 years old with an ABCD1 genetic mutations, and who
-
bluebird bio reveals long-term data for Lenti-D gene therapy in CALD
bluebird bio has revealed new data from its clinical development programme for Lenti-D gene therapy in cerebral adrenoleukodystrophy (CALD). ... In October 2020, the European Medicines Agency (EMA) accepted a marketing authorisation application (MAA) for
-
EMA accepts application for bluebird bio’s Lenti-D in CALD
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for bluebird bio’s Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD). ... Bluebird bio's Lenti-D (eli-cel/elivaldogene autotemcel) is a potential
-
bluebird bio reveals further encouraging data for CALD gene therapy
Bluebird's treatment works by extracting patients' stem cells and modifying them with Lenti-D. ... There were three adverse events potentially related to treatment of Lenti-D, but these resolved using standard measures.
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and life-threatening hereditary neurological disorder.
-
Bluebird Bio: on the cusp of a gene therapy revolution
Bluebird’s four breakthrough candidates. In addition to the two LentiGlobin-based treatments, the company also has its Lenti-D product for patients with cerebral adrenoleukodystrophy (CALD), a rare, serious and ... A New England Journal of Medicine
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Cuttsy + Cuttsy
Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
